Zhejiang Yinggelai Pharmaceutical Co. Ltd.

Primary study objective: To study the pharmacokinetics of the test preparation Sitagliptin Metformin Tablets (Specifications: Sitagliptin 50mg/Metformin 850mg, produced by Zhejiang Ingel Pharmaceutical Co., Ltd.) and the reference preparation Sitagliptin Metformin Tablets (II) (Janoda®, Specifications: Sitagliptin 50mg/Metformin 850mg, licensed by MSD Pharma (Singapore) Pte. Ltd, produced by Patheon Puerto Rico, Inc. (Manati)) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objective: To study the safety of the test preparation Sitagliptin Metformin Tablets and the reference preparation Sitagliptin Metformin Tablets (II) (Janoda®) in healthy adult subjects after a single oral administration in the fasting and fed state.

Main study objectives: To study the pharmacokinetics of the test preparation valsartan hydrochlorothiazide tablets (specification: 80/12.5mg (each tablet contains 80mg valsartan, 12.5mg hydrochlorothiazide), produced by Zhejiang Yinggelai Pharmaceutical Co., Ltd.) and the reference preparation valsartan hydrochlorothiazide tablets (Co-Diovan®, specification: 80/12.5mg (each tablet contains 80mg valsartan, 12.5mg hydrochlorothiazide), produced by Novartis Farma S.p.A. (I).Italy) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objectives: To evaluate the safety of the test preparation and reference preparation of valsartan hydrochlorothiazide tablets in healthy subjects after a single oral administration in the fasting and fed state.